1. Market Research
  2. > Biolink Group AS - Product Pipeline Review - 2013

Biolink Group AS - Product Pipeline Review - 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 20 pages

Biolink Group AS - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Biolink Group AS - Product Pipeline Review - 2013” provides data on the Biolink Group AS’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Biolink Group AS’s corporate website, SEC filings, investor presentations and featured press releases, both from Biolink Group AS and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Biolink Group AS - Brief Biolink Group AS overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biolink Group AS human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Biolink Group AS with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biolink Group AS’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Biolink Group AS’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biolink Group AS in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biolink Group AS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biolink Group AS.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biolink Group AS and identify potential opportunities in those areas.

Table Of Contents

Biolink Group AS - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Biolink Group AS Snapshot 4
Biolink Group AS Overview 4
Key Information 4
Key Facts 4
Biolink Group AS - Research and Development Overview 5
Key Therapeutic Areas 5
Biolink Group AS - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Biolink Group AS - Pipeline Products Glance 9
Biolink Group AS Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Biolink Group AS - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Biolink Group AS - Drug Profiles 11
CAN-C/D-3G 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
CIF-C/D-3G 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
HPT-C/D-3G 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Biolink Group AS - Pipeline Analysis 14
Biolink Group AS - Pipeline Products by Therapeutic Class 14
Biolink Group AS - Pipeline Products By Target 15
Biolink Group AS - Pipeline Products by Route of Administration 16
Biolink Group AS - Pipeline Products By Mechanism of Action 17
Biolink Group AS - Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20



List of Tables

Biolink Group AS, Key Information 4
Biolink Group AS, Key Facts 4
Biolink Group AS - Pipeline by Indication, 2013 6
Biolink Group AS - Pipeline by Stage of Development, 2013 7
Biolink Group AS - Monotherapy Products in Pipeline, 2013 8
Biolink Group AS - Phase I, 2013 9
Biolink Group AS - Preclinical, 2013 10
Biolink Group AS - Pipeline By Therapeutic Class, 2013 14
Biolink Group AS - Pipeline By Target, 2013 15
Biolink Group AS - Pipeline By Route of Administration, 2013 16
Biolink Group AS - Pipeline Products By Mechanism of Action, 2013 17



List of Figures

Biolink Group AS - Pipeline by Indication, 2013 6
Biolink Group AS - Pipeline by Stage of Development, 2013 7
Biolink Group AS - Monotherapy Products in Pipeline, 2013 8
Biolink Group AS - Pipeline By Therapeutic Class, 2013 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.